Streetbeat News

Analyst Ratings

ATVI

Benchmark analyst Mike Hickey reiterated a Buy rating on Activision Blizzard (NASDAQ:ATVI) and maintained a $90 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 12:30 pm

AAPL

Wedbush analyst Daniel Ives maintains an Outperform rating on Apple (NASDAQ:AAPL) and raises the price target from $205 to $220.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 12:28 pm

BASE

Wedbush analyst Taz Koujalgi reiterated a Neutral rating on Couchbase (NASDAQ:BASE) and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 12:26 pm

G

Wedbush analyst Moshe Katri reiterated a Neutral rating on Genpact (NYSE:G) and maintained a $45 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 12:25 pm

CTSH

Wedbush analyst Moshe Katri has reiterated an Outperform rating on Cognizant Tech Solns (NASDAQ:CTSH) and maintained a $75 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 12:24 pm

BASE

CIEN

CNM

JBHT

NFLX

PSX

SJM

SPTN

THO

TTD

XPO

Several analyst firms have updated their price targets for various US-listed companies, including Netflix, J.B. Hunt Transport Services, Couchbase, SpartanNash, XPO, Core & Main, Phillips 66, The Trade Desk, THOR Industries, Ciena Corporation, and The J. M. Smucker Company.

Portfolio Pulse from Lisa Levin

June 07, 2023 | 12:23 pm

ASO

Wedbush analyst Seth Basham maintains an Outperform rating on Academy Sports (NASDAQ:ASO) but lowers the price target from $75 to $60.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 12:20 pm

REPL

Wedbush analyst Robert Driscoll reiterated an Outperform rating on Replimune Group (NASDAQ:REPL) and maintained a $52 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 12:17 pm

ZNTL

Wedbush analyst Robert Driscoll reiterated an Outperform rating on Zentalis Pharma (NASDAQ:ZNTL) and maintained a $38 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 12:16 pm

ASND

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Ascendis Pharma (NASDAQ:ASND) and maintained a $187 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 12:15 pm